GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (FRA:52U) » Definitions » Payments of Debt

Hyloris Pharmaceuticals (FRA:52U) Payments of Debt : €-0.01 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Hyloris Pharmaceuticals Payments of Debt?

Hyloris Pharmaceuticals's Payments of Debt for the six months ended in Dec. 2023 was €-0.01 Mil.

Hyloris Pharmaceuticals's Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.01 Mil.


Hyloris Pharmaceuticals Payments of Debt Historical Data

The historical data trend for Hyloris Pharmaceuticals's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals Payments of Debt Chart

Hyloris Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Payments of Debt
Get a 7-Day Free Trial -0.05 -8.10 -0.06 -7.38 -0.01

Hyloris Pharmaceuticals Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 -1.06 -6.32 - -0.01

Hyloris Pharmaceuticals Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hyloris Pharmaceuticals Payments of Debt Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's Payments of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Hyloris Pharmaceuticals (FRA:52U) Business Description

Traded in Other Exchanges
Address
Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.

Hyloris Pharmaceuticals (FRA:52U) Headlines

No Headlines